Should I buy or sell Solid Biosciences stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLDB shares. View SLDB analyst ratings or view top-rated stocks .

What is Solid Biosciences' stock price target for 2024?

6 equities research analysts have issued 12 month target prices for Solid Biosciences' stock. Their SLDB share price targets range from $16.00 to $21.00. On average, they predict the company's stock price to reach $18.25 in the next twelve months. This suggests a possible upside of 103.2% from the stock's current price. View analysts price targets for SLDB or view top-rated stocks among Wall Street analysts .

How have SLDB shares performed in 2024?

Solid Biosciences' stock was trading at $6.14 at the beginning of 2024. Since then, SLDB stock has increased by 46.3% and is now trading at $8.98. View the best growth stocks for 2024 here .

Are investors shorting Solid Biosciences?

Solid Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 920,900 shares, an increase of 49.8% from the March 15th total of 614,900 shares. Based on an average daily volume of 362,300 shares, the short-interest ratio is presently 2.5 days. Approximately 3.1% of the shares of the stock are sold short. View Solid Biosciences' Short Interest .

When is Solid Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SLDB earnings forecast .

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc. (NASDAQ:SLDB) announced its quarterly earnings results on Wednesday, March, 13th. The company reported ($1.00) EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $0.01.

When did Solid Biosciences' stock split?

Solid Biosciences's stock reverse split before market open on Friday, October 28th 2022. The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Solid Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Selecta Biosciences (SELB) , VBI Vaccines (VBIV) , Inovio Pharmaceuticals (INO) , Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Catalyst Pharmaceuticals (CPRX) , Cidara Therapeutics (CDTX) , SCYNEXIS (SCYX) , Verastem (VSTM) and Agile Therapeutics (AGRX) .

When did Solid Biosciences IPO?

Solid Biosciences (SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers.

How do I buy shares of Solid Biosciences?

Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:SLDB

Solid Biosciences (SLDB) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free SLDB Stock Alerts

$8.70

-0.56 (-6.05%)

(As of 04:00 PM ET)

Compare

Today's Range: $8.66
▼
$9.34
50-Day Range: $7.78
▼
$14.75
52-Week Range: $1.81
▼
$15.05

Volume: 113,857 shs
Average Volume: 329,299 shs
Market Capitalization: $329.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.25

Get Solid Biosciences alerts:

Solid Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 103.2% Upside
$18.25 Price Target
Short Interest: Healthy
3.05% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$1,111 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.64) to ($2.48) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.67 out of 5 stars

Medical Sector

246th out of 918 stocks

Biological Products, Except Diagnostic Industry

34th out of 151 stocks

4.5

Analyst's Opinion

Consensus Rating
Solid Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Solid Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
3.05% of the float of Solid Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Solid Biosciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Solid Biosciences has recently increased by 49.76%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Solid Biosciences does not currently pay a dividend.
Dividend Growth
Solid Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SLDB.

2.7

News and Social Media Coverage

News Sentiment
Solid Biosciences has a news sentiment score of 1.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Solid Biosciences this week, compared to 1 article on an average week.
Search Interest
Only 9 people have searched for SLDB on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Solid Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,111.00 in company stock.
Percentage Held by Insiders
19.33% of the stock of Solid Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Solid Biosciences are expected to grow in the coming year, from ($2.64) to ($2.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Solid Biosciences is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Solid Biosciences is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Solid Biosciences has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Solid Biosciences Stock (NASDAQ:SLDB)

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

SLDB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SLDB Stock News Headlines

April 10, 2024 | seekingalpha.com

Buy Solid Biosciences: Unpacking Its Main Value Driver

April 3, 2024 | globenewswire.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 1, 2024 | markets.businessinsider.com

Solid Biosciences: FDA Grants Rare Pediatric Disease Designation For SGT-003

April 1, 2024 | globenewswire.com

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

March 28, 2024 | msn.com

William Blair starts Solid Biosciences at outperform

March 27, 2024 | finance.yahoo.com

Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium

March 24, 2024 | finance.yahoo.com

SLDB Apr 2024 7.500 put

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 19, 2024 | markets.businessinsider.com

Cautious Optimism Amidst Clinical Progress and Regulatory Hurdles for Solid Biosciences

March 18, 2024 | markets.businessinsider.com

Solid Biosciences (SLDB) Gets a Buy from Barclays

March 16, 2024 | finance.yahoo.com

SLDB Sep 2024 17.500 call

March 14, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Solid Biosciences on Promising Pipeline and Financial Stability

March 13, 2024 | finanznachrichten.de

Solid Biosciences Inc.: Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

March 13, 2024 | markets.businessinsider.com

Solid Biosciences Stock Drops 4% Due To Wider Loss In Q4

March 13, 2024 | msn.com

Solid Biosciences, Cue Biopharma, Annexon among healthcare movers

March 13, 2024 | globenewswire.com

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

March 11, 2024 | realmoney.thestreet.com

Solid Biosciences price target raised by $7 at H.C. Wainwright, here's why

March 11, 2024 | markets.businessinsider.com

Leerink Partners Keeps Their Hold Rating on Solid Biosciences (SLDB)

March 7, 2024 | msn.com

Solid Biosciences signs agreement with Armatus Bio for AAV-SLB101

March 7, 2024 | finance.yahoo.com

Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD

February 22, 2024 | benzinga.com

Solid Biosciences Stock (NASDAQ:SLDB) Insider Trades

February 22, 2024 | benzinga.com

Solid Biosciences Stock (NASDAQ:SLDB), Short Interest Report

February 18, 2024 | msn.com

Insider Buying: Taking a Controlling Stake in a Struggling Retailer?

February 17, 2024 | finance.yahoo.com

SLDB Mar 2024 10.000 put

February 6, 2024 | markets.businessinsider.com

Hold Rating on Solid Biosciences Amid Gene Therapy Developments and Regulatory Milestones

January 23, 2024 | investing.com

Solid Biosciences LLC (SLDB)

See More Headlines

Receive SLDB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:SLDB
CUSIP: N/A
CIK: 1707502
Web: www.solidbio.com
Phone: (617) 337-4680
Fax: N/A
Employees: 88
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.25
High Stock Price Target: $21.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +102.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-96,010,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -62.11%
Return on Assets: -48.99%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 8.94
Quick Ratio: 8.94

Sales & Book Value

Annual Sales: $8.09 million
Price / Sales: 42.18
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.27 per share
Price / Book: 1.44

Miscellaneous

Outstanding Shares: 37,830,000
Free Float: 30,521,000
Market Cap: $341.23 million
Optionable: Optionable
Beta: 1.93

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Ian F. Smith A.C.A. (Age 58)
C.P.A., Executive Chair
Comp: $75k
Mr. Alexander G. Cumbo (Age 53)
President, CEO & Director
Comp: $1.82M
Mr. Ilan Ganot (Age 50)
Co-founder, Strategic Advisor to the CEO & Director
Comp: $1.36M
Mr. David Tyronne Howton Jr. (Age 52)
J.D., COO & Secretary
Comp: $1.4M
Mr. Gilad David Hayeem (Age 56)
Co-Founder
Ms. Annie Ganot
Co-Founder & Head of Patient Advocacy
Dr. Andrey Juan Zarur Ph.D. (Age 53)
Co-Founder
Comp: $90.17k
Mr. Kevin Tan C.F.A. (Age 47)
CFO & Treasurer
Mr. Stephen J. Di Palma M.B.A. (Age 65)
Treasurer & Principal Accounting Officer
Mr. Paul Herzich (Age 46)
Chief Technology Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SLDB Stock Analysis - Frequently Asked Questions

Should I buy or sell Solid Biosciences stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLDB shares.
View SLDB analyst ratings or view top-rated stocks.
What is Solid Biosciences' stock price target for 2024?: 6 equities research analysts have issued 12 month target prices for Solid Biosciences' stock. Their SLDB share price targets range from $16.00 to $21.00. On average, they predict the company's stock price to reach $18.25 in the next twelve months. This suggests a possible upside of 103.2% from the stock's current price.
View analysts price targets for SLDB or view top-rated stocks among Wall Street analysts.
How have SLDB shares performed in 2024?: Solid Biosciences' stock was trading at $6.14 at the beginning of 2024. Since then, SLDB stock has increased by 46.3% and is now trading at $8.98.
View the best growth stocks for 2024 here.
Are investors shorting Solid Biosciences?: Solid Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 920,900 shares, an increase of 49.8% from the March 15th total of 614,900 shares. Based on an average daily volume of 362,300 shares, the short-interest ratio is presently 2.5 days. Approximately 3.1% of the shares of the stock are sold short.
View Solid Biosciences' Short Interest.
When is Solid Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SLDB earnings forecast.
How were Solid Biosciences' earnings last quarter?: Solid Biosciences Inc. (NASDAQ:SLDB) announced its quarterly earnings results on Wednesday, March, 13th. The company reported ($1.00) EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $0.01.

When did Solid Biosciences' stock split?: Solid Biosciences's stock reverse split before market open on Friday, October 28th 2022. The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Solid Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Selecta Biosciences (SELB), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Cidara Therapeutics (CDTX), SCYNEXIS (SCYX), Verastem (VSTM) and Agile Therapeutics (AGRX).
When did Solid Biosciences IPO?: Solid Biosciences (SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers.
How do I buy shares of Solid Biosciences?: Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLDB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Solid Biosciences (SLDB) Stock Price, News & Analysis

Solid Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Solid Biosciences Stock (NASDAQ:SLDB)

SLDB Stock Price History

SLDB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SLDB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™